Brind.

Maruti Suzuki and Aurobindo Pharma face price hikes due to input costs, while Aurobindo establishes a biosimilars facility in Hyderabad and receives ANVISA approval.

1 report, 1 independent Updated Jul 1

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

Maruti Suzuki Aurobindo Pharma

Keep exploring

The entities involved

Maruti Suzuki
Japanese-Indian automobile manufacturer
- Kia, BMW, Honda, Toyota, and Hyundai are competing in the Indian auto market with expected new model launches.Fri 17:04
- Suzuki and Maruti Suzuki are developing new engine technology and exploring technology transfer for product portfolio expansion in India.Fri 13:27
Aurobindo Pharma
an Indian pharmaceutical company
- MSD and Aurobindo Pharma signed a voluntary licensing agreement for generic alimatravir.Mon 05:30

Coverage

Newest first; wire copies grouped

Jul 1moneycontrol.com